ARTICLE | Clinical News
BTA585: Phase IIa suspended enrollment
June 20, 2016 7:00 AM UTC
Aviragen voluntarily suspended enrollment in a double-blind, placebo-controlled, U.K. Phase IIa trial of oral BTA585 after 1 subject had “an increase of a cardiac enzyme level coupled with transient E...